Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $14
Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $16 to $14.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
Heron Therapeutics Granted FDA Manufacturing Approval For Cinvanti
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209296
36 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday.
Heron Therapeutics: Q4 Earnings Insights
Heron Therapeutics (NASDAQ:HRTX) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.